Beraprost sodium

• CAT Number: I017308
• CAS Number: 496807-11-5
• Molecular Formula: C24H29NaO5
• Molecular Weight: 420.48
• Purity: ≥95%
• IUPAC Name: sodium 4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
• InChI: InChI=1S/C24H30O5.Na/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28;/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28);/q;+1/p-1/b13-12+;/t15?,17-,19+,20+,21-,23-;/m0./s1
• InChIKey: YTCZZXIRLARSET-VJRSQJMHSA-M
• SMILES: CC#CCC(C)[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C3=CC=CC(=C3O2)CCCC(=O)[O-])O)O.[Na+]

Beraprost Sodium(CAT: I017308) is an orally active prostacyclin (PGI₂) analog with potent vasodilatory, antiplatelet, and cytoprotective properties. By stimulating prostacyclin (IP) receptors, it enhances cyclic AMP (cAMP) signaling, leading to inhibition of platelet aggregation, relaxation of vascular smooth muscle, and improved endothelial function. Clinically, Beraprost has been investigated for the treatment of pulmonary arterial hypertension (PAH), peripheral arterial disease, and other cardiovascular disorders. It also exhibits anti-inflammatory and anti-proliferative effects, making it useful in vascular biology research. With its dual clinical and experimental relevance, Beraprost Sodium is a valuable tool for cardiovascular and pulmonary disease research.